In the current clinical context, drug dosing in oncology is dictated by toxicity. The optimal
dosages of drugs in combinatory regimens for solid tumours are not clear, and the typical
physician's decision on dose adjustment is a clinical judgement based on the degree of
toxicity experienced by the patient. CURATE.AI - a small data, AI-derived technology platform
- allows personalised guidance of an individual's dose modulations based only on that
individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts
to changes experienced by the subject, providing dynamic dose optimisation throughout the
duration of the subject's treatment. This study aims to demonstrate the feasibility of
applying CURATE.AI in standard of care settings for treatment of solid tumours. An additional
objective is to explore tumour markers in serial measurements at weekly frequency of probing,
with modulated doses.